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http://dx.doi.org/10.1016/j.jmii.2013Background: Group A streptococcus (GAS) is a common pathogen in children. Macrolide resis-
tance in GAS has been described worldwide. The aims of this study are to analyze macrolide
resistance of GAS isolates in southern Taiwan and to clarify the relationship of emm typing
and macrolide resistance in the past decade.
Methods: All GAS isolated from patients younger than 18 years at a single tertiary center in
southern Taiwan were collected from 2000 to 2012. Antibiotics susceptibility to erythromycin,
azithromycin, and clindamycin were determined by agar dilution method, and were inter-
preted by Clinical and Laboratory Standards Institute (CLSI) standards. emm typing was per-
formed by polymerase chain reaction (PCR).
Results: A total of 301 isolates were collected during the period of 13 years. Scarlet fever
(38.5%) and acute pharyngitis (32.2%) were the most common diagnosis. Decreased resistance
rate of erythromycin from 53.1% in 2000 to 0% in 2010 was found, but it increased rapidly to
65% in 2011. The resistance rate of azithromycin was the lowest (4.2%) in 2005, but was higher
than 15% after 2006. The involvement of the erythromycin resistance genes were mefA
(53.1%), ermB (35.9%), and ermTR (10.9%). The resistance of clindamycin also increased sinceof Pediatrics, National Cheng Kung University Hospital, Number 138, Sheng-Li Road, Tainan 70403,
du.tw (C.-C. Liu).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Macrolide resistance of GAS in children 1612011. emm12 was the most common serotype and accounted for 44.9% of all isolates.
Compared with the non-emm12 group, resistance to erythromycin, azithromycin, and clinda-
mycin were more frequently detected in the emm12 group.
Conclusion: Increased resistance of GAS to macrolide and clindamycin was found in recent
years. emm12 was the main serotype for macrolide resistance.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Group A Streptococcus (GAS, or Streptococcus pyogenes)
causes a wide range of clinical illness, including phar-
yngotonsillitis, scarlet fever, sepsis, and toxic shock syndrome
in children. Penicillin is the first-line drug of choice for the
treatment of GAS infection. Erythromycin is an alternative
choice in persons who are allergic to penicillin. Azithromycin,
which is given inadaily doseand short course, iswidelyused in
clinical practice for the treatment of respiratory tract infec-
tion, such as Mycoplasma pneumoniae infection.
However, macrolide resistance had been described
worldwide since the 1990s. In Finland, the resistance rate of
GAS to erythromycin from blood cultures increased from 4% in
1988 to 24% in 1990, and the erythromycin resistance was
associatedwith theconsumptionofmacrolide.1,2 In theUnited
States, ahigherythromycin resistance rate (48%)was reported
in schoolchildren in Pittsburgh between 2000 and 2001.3
In Taiwan, Hsueh et al4 reported decreased susceptibil-
ity of erythromycin to GAS in 1992 and 1993. They
demonstrated decreased erythromycin resistance of GAS in
1999 to 2003 from 46% to 17%.5 The relationship was found
between decreased resistance rate and decreased eryth-
romycin consumption because of governmental policy in
the restriction of antibiotics treatment in Taiwan. However,
there are no available data for the susceptibility rate in
recent years in Taiwan.
The aims of this study are to analyze macrolide resis-
tance of GAS isolates at a medical center in southern
Taiwan and to clarify the relationship of emm typing and
macrolide resistance in the past decade.Materials and methods
Patient enrollment and definition
All GAS isolates were collected from 2000 to 2012 from
patients younger than 18 years at a 1200-bed tertiary
medical center, National Cheng Kung University Hospital
(NCKUH) in southern Taiwan. Demographic data, including
age, sex, diagnosis, and culture sites were reviewed. The
diagnosis is based on the following definitions. Acute
pharyngitis was defined as clinical symptoms such as fever
and sore throat or injected pharynx on physical examina-
tion. Scarlet fever was defined as fever with strawberry
appearance of the tongue, and diffuse erythematous rash
with sandpaper-like consistency. Cellulitis was defined as
inflammation of the skin and subcutaneous tissue sur-
rounding the infection site. Necrotizing fasciitis wasdefined as infection over the deep subcutaneous tissue and
fascia with rapid progression. Streptococcal toxic shock
syndrome was defined according to the definition from The
Working Group on Severe Streptococcal Infections.6
In a single patient with multiple isolates from different
sites, only the isolate from a sterile site, such as blood or
pus, was included. Isolates with culture report showed S.
pyogenes initially, but emm typing showed other group
streptococcus were also excluded.
All informed consent forms and relevant study-related
documentation were approved by a third-party Institutional
Review Board.
Microbiologic features
Antibiotics susceptibility was determined by agar dilution
method with Mueller Hinton agar supplemented with 5%
sheep blood. The minimum inhibitory concentrations (MICs)
of erythromycin, azithromycin, and clindamycin were
recorded, and the MICs were interpreted according to the
criteria from the Clinical and Laboratory Standards Institute
(CLSI).7 The MICs of erythromycin 0.25 mg/mL was sus-
ceptible, 0.5 mg/mL was intermediate, and 1.0 mg/mL was
resistant. As for azithromycin, cut points of susceptible,
intermediate, and resistant isolates were 0.5 mg/mL,
1.0 mg/mL, and 2.0 mg/mL, respectively. The cut points of
susceptible, intermediate, and resistant isolates were
0.25 mg/mL, 0.5 mg/mL and 1.0 mg/mL, respectively, for
clindamycin. MIC50 and MIC90 of isolates to erythromycin,
azithromycin, and clindamycin were also measured every
year. Isolates with intermediate susceptibility to azi-
thromycin (MIC Z 1.0 mg/mL) were rechecked with E-test.
emm typing
Polymerase chain reaction (PCR) amplification of the emm
gene was performed with previously described primers.8
The amplicons were sequenced on a 2720 Thermal Cycler
(Applied Biosystems, Foster City, CA, USA) with the primer
pair for PCR. The emm sequences obtained were inter-
preted according to the database established by the United
States Centers for Disease Control and Prevention (CDC).9
An isolate was considered to be of a given emm type if it
had >98% identity over the first 180 bases obtained.
Detection of erythromycin resistance genes
PCR assay is used to identify the genetic mechanism of
resistance. ThemefA, ermB, and ermTR resistance genes of
162 P.-K. Chuang et al.isolates with erythromycin MIC 0.5 mg/mL were detected
by PCR amplification with the use of previously described
primers.10,11 GAS isolates that were susceptible to eryth-
romycin, obtained during the study period, were used as
negative controls. Positive control strains yielding the ex-
pected products sizes of were 348 bp, 639 bp, and 206 bp
for mefA, ermB, and ermTR, respectively.
Pulse-field gel electrophoresis analysis
The pulse-field gel electrophoresis (PFGE) protocol for GAS
wasdevelopedon thebasis ofGautom’sEscherichia coli rapid
PFGE protocol, with minor modifications.12 Briefly, the indi-
vidual GAS colonies were grown on blood agar plates and
incubated in 5% CO2 at 37 C. Following suspension in sus-
pension buffer (100 mM Tris and 100 mM EDTA) and washing,
the bacterial pelletwas resuspended in suspension buffer. An
agarose preparation [1% Seakem Gold agarose (FMC Bio-
Products, Rockland, Maine, USA) with 1% sodium dodecyl
sulfate (SDS) in Tris-EDTA buffer (10 mM Tris and 1 mM EDTA,
pH 8)] was mixed with each suspension. The bacterium-
agarose mixture was then added to plug molds (Bio-Rad
Laboratories, Hercules, CA, USA). After solidification, the
plugs were transferred to centrifugation tubes containing
lysis buffer (50 mM Tris, 50 mM EDTA, 1% sodium lauryl sar-
cosine, 0.5mgproteinaseK; pH8) and incubatedat 50 C for 2
hours. After the completion of the agarose plug preparation,
plug slices were made and digested with SmaI. The DNA
fragments were separated by electrophoresis in 1% agarose
gels at 14 C in Tris-borate-EDTA buffer (pH 8). The gels were
stained with ethidium bromide, destained with water,
exposed on a UV transilluminator, and photographed. Bio-
Numerics 6.5 (Applied Maths, Sint-Martens-Latem, Belgium)
was used to analyze PFGE images, and isolates with the same
emm type sharing PFGE pattern with >80% similarity were
considered to be similar strains.
Statistical analysis
All statistical analyses were conducted using the SPSS
version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Data
were analyzed to determine the statistical significance of
differences between antibiotics resistance and emm
typing. A p value <0.05 was considered statistically
significant.
Results
Demographic data
A total of 301 isolates were collected during a 13-year
period (range: 7-46 isolates/y). The mean age of patients
was 7.6  3.4 years (6 days old-17.7 years old), and male
sex was predominant (58.5%). Scarlet fever (38.5%) and
acute pharyngitis (32.2%) were the most common diagnosis.
Overall, 19 patients (6.3%) had severe infection with
streptococcal toxic shock syndrome (4.3%), sepsis (3.7%), or
necrotizing fasciitis (1.3%). Most of the isolates (70.8%)
were obtained from the throat, followed by pus or a wound.
Eleven (3.7%) isolates were obtained from blood.Susceptibility and MIC50/90
The resistance rates of erythromycin were high in 2000
(53.1%) and 2001 (57.1%), but it decreased rapidly to 15.6%
in 2002 (Fig. 1). Resistance rates were lower than 25% be-
tween 2002 and 2010, and were 0% in 2009 and 2010.
However, it increased rapidly to 65% in 2011, and 44.4% in
2012. As for azithromycin, high resistance rates (>50%)
were also found in 2000 and 2001. It decreased to lower
than 25% in the following 5 years, which is the same as
erythromycin, and the lowest resistance rate of azi-
thromycin was 4.2% in 2005. But it increased rapidly to
59.1% in 2007 and was higher than 30% after 2010. Clinda-
mycin had a low resistance rate below 10% for many years.
However, similar to erythromycin and azithromycin, the
resistance rate of clindamycin increased rapidly after 2011.
Overall, 63 isolates (20.9%)were resistant to erythromycin,
82 isolates (27.2%) were resistant to azithromycin, and 33
isolates (11.0%) were resistant to clindamycin. Sixty-one iso-
lates in 63 erythromycin-resistant strains (96.8%) were also
resistant to azithromycin, and all clindamycin resistant iso-
lateswere resistant toazithromycin. In azithromycin-resistant
strains, 61 isolates (74.4%)were resistant toerythromycin,and
33 isolates (40.2%) were resistant to clindamycin.
Regarding MIC90 of erythromycin, we found that the MIC
level was high prior to 2001 (MIC90: 256 mg/mL in 2000,
16 mg/mL in 2001), then it decreased gradually since 2003
(Fig. 2). Another minor elevation of MIC90 was found during
2007 and 2008, then it declined in the following 2 years.
However, there was a rapid increase since 2011 (MIC90:
128 mg/mL). As for azithromycin, the MIC90 level was also
high prior to 2001, and it decreased in the following years.
The MIC90 of azithromycin, erythromycin, and clindamycin
were significantly increased after 2010. The MIC90 of azi-
thromycin was higher than erythromycin and clindamycin.
The MIC50 of azithromycin, erythromycin, and clindamycin
also peaked in 2011 (data are not shown).
emm typing and resistance
In total, 23 different emm types were identified. emm12
was the most common serotype, which accounted for 44.9%
of all isolates (n Z 135), followed by emm1 (19.6%) and
emm4 (17.9%). emm12, emm1, and emm4 account for
82.4% of all isolates.
The distribution of emm types by year are shown in Fig. 3.
emm12 is the leading serotype in 8 years, and were pre-
dominantly more than other types (>50%) in 2000, 2001,
2005, 2006, 2011, and 2012. emm1were predominant in 2002
and 2003, and emm4 were predominant in 2004 and 2008.
In those years when emm12 were predominant, the an-
tibiotics resistance rates were relatively higher. In com-
parison with the non-emm12 group, emm12 was found to
have higher resistance to erythromycin (28.1% vs. 15.1%,
pZ 0.004), azithromycin (39.3% vs. 17.5%, p < 0.001), and
clindamycin (19.3% vs. 4.2%, p < 0.001).
Erythromycin resistance genes
Erythromycin resistance genes with mefA, ermB, ermTR
were detected in 65 erythromycin nonsusceptible isolates
Figure 1. Antibiotic resistance rates of group A streptococci to erythromycin, azithromycin, and clindamycin between 2000 and
2012 at National Cheng Kung University Hospital in Tainan City, Taiwan.
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63 isolates. Two genes (mefA, ermB) were detected in one
isolate. No resistance gene was detected in two isolates.
Overall, mefA accounted for 53.1% (n Z 34), ermB
accounted for 35.9% (n Z 23), and ermTR accounted for
10.9% (n Z 7). Fig. 4 showed the resistance gene distribu-
tion by year.mefA gene was predominant prior to 2008, and
ermB gene was predominant after 2011.
PFGE analysis
Increased macrolide resistant emm12 isolates were detec-
ted in 2011 and 2012. Six erythromycin-resistant emm12
isolates in 2011 and three in 2012 were collected randomly
to perform the PFGE study. The result showed almost the
same patterns among these nine isolates with more than
90% similarity (Fig. 5).
Discussion
A macrolide-resistant strain of GAS has been reported
worldwide and has been an ongoing problem since the
1990s. A nationwide study in Finland showed a steady
decline in erythromycin resistance rate, from 16.5% in 1992
to 8.6% in 1996.2 This decline was related to reductions in
the use of macrolide for respiratory and skin infection inFigure 2. Annual trend of MIC90 (mg/mL) for azithromycoutpatients by nationwide recommendation. Another study
further confirmed the relationship between decreased
macrolide consumption and declined erythromycin resis-
tance. During 1997e2001, the regional erythromycin re-
sistances of GAS in Finland were related to the macrolide
consumption of the previous year.13
In the United States, the macrolide resistance among
GAS was low prior to 2000. But high resistance rate to
erythromycin was found between 2000 and 2001.3 It was
reported that 48% of isolates from school children were
resistant to erythromycin, and 38% of isolates obtained
from the community were resistant to erythromycin. This
outbreak was due to a single strain, and emm6 was the
major resistant strain. A large nationwide study showed 129
of 1885 isolates (6.8%) were erythromycin resistant, 130
(6.9%) were azithromycin resistant, and 10 (0.5%) were
clindamycin resistant between 2002 and 2003.14 emm
typing showed the 129 erythromycin-resistant strains
belonged to 44 PFGE patterns and 28 emm types.
In France, the erythromycin resistance rate was 22.4% in
isolates collected from children age 2e16 years with acute
pharyngitis between 2002 and 2003.15 In one study per-
formed in Portugal during 2000e2006, the asymptomatic
colonization rate was 10.7% in children. The macrolide
resistance rate was 16.5%, whereas the rate was higher
among children age 0e6 years (18.2%) and among adults
(16.2%) than among children age 7e16 years (8.4%).16 Inin, erythromycin, and clindamycin during 2000e2012.
Figure 3. Annual trends in the distribution of emm types of group A streptococci during 2000e2012.
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found between 1994 and 2006, and the resistance rate to
clindamycin and tetracycline was 6.5% and 6.8%, respec-
tively.17 In China, the resistance rates of clarithromycin,
erythromycin, and azithromycin were 98.1%, 97.6%, and
97.2%, respectively. High clindamycin and tetracycline
resistance rates (97.2% and 94.0%, respectively) were also
found.18
However, in some areas of Europe and South America,
the erythromycin resistance rates of GAS were low. In
Norway, the erythromycin resistance rate was 2.7% within
three separate periods from 1993 to 2002.19 The erythro-
mycin resistance rate was 2.6% during 2006e2009 in Ger-
many. Low azithromycin and clindamycin resistance rates
were also found (1.4% and 0.9%, respectively).20 One study
in Brazil showed that none of the 130 isolates collected
from symptomatic children were resistant to erythromycin,
azithromycin, or clindamycin.21
Although resistance rates to macrolide were high
worldwide, the rates decreased in some countries gradually
under antimicrobial stewardship program. In France, the
resistance rate to erythromycin was high (22.4%) between
2002 and 2003 and as previously mentioned, it decreased to
12% between 2005 and 2006. It further declined to 3.2% in
children with acute pharyngitis between 2009 and 2011 due
to decreased macrolide consumption.22 In Belgium, a large
study showed decreased macrolide resistance from 13.5% in
1999 to 3.3% in 2006.23 It was related to decreased con-
sumption of macrolides, lincosamides, streptogramin B,
and tetracycline.
In 2001, the SMART (Surveillance from Multicenter
Antimicrobial Resistance in Taiwan) program collected
isolates from nine hospitals in different parts of Taiwan,
and the non-susceptibility rate to erythromycin was 78%
(54% were intermediate, and 24% were resistant), and the
nonsusceptibility rate to clindamycin was 5%.24 In the cur-
rent study, the erythromycin resistance rate were 53e57%
in 2000 and 2001.
However, the resistance rate to erythromycin in Taiwan
has decreased since 2002. Hsueh et al5 demonstrated
decreased erythromycin resistance in GAS, at 46% in 1999 to17% in 2003 from three major hospitals in Taiwan, and the
relationship was observed between decreased erythro-
mycin consumption and decreased resistance rate. The
decline in erythromycin use was due to Taiwan govern-
mental policy beginning in February 2001 to deny reim-
bursement through the National Health Insurance (NHI)
system for the costs of antibiotics for the treatment of
acute upper respiratory tract infection without evidence of
bacterial involvement.
Through implementation of regulations of antibiotics
use, there was 33% total reduction of antimicrobials from
29.7 defined daily doses (DDDs) in 1999 to 19.8 DDDs in 2001
in ambulatory patients, and the use of erythromycin
declined from 0.447 per 1000 inhabitants per day in 2000 to
0.129 DDDs per 1000 inhabitants per day in 2003.25,26
Our previous study in southern Taiwan showed a reduc-
tion in resistance rates among children, from 77% during
1997e1999 to 15% during 2002e2004.27 Lo et al28 showed
decreased erythromycin resistance rates, from 40.7% dur-
ing 1999e2002 to 24.7% during 2003e2005 in northern
Taiwan. They also demonstrated low resistance rates (8%)
in children with scarlet fever and pharyngitis during
2000e2011.29 Another study showed a 6.8% erythromycin
resistance rate from skin and soft tissue infections, whereas
emm106 and emm11 were predominant.30 The current
study showed a significant decreased resistance rate to
erythromycin and azithromycin since 2002. However, the
resistance to macrolide has increased again since 2007.
Methylation of a ribosomal target and active efflux of
erythromycin are the two leading factors involved in the
resistance of streptococci to macrolides.31 The predomi-
nant erythromycin-resistant mechanism of GAS strains
varies in different geographic areas. Surveillance studies
clearly showed mefA-mediated resistance prevailed in
Mexico (95%) and Spain (89.5%), whereas the ermB pre-
dominates in China (90.3%) and France (69.4%), and ermTR
predominated in United States (56%).15,17,18,32 In the cur-
rent study, mefA remained the major mechanism in
southern Taiwan between 2000 and 2008, but ermB-con-
tained isolates dominated in 2011 and 2012. Whether the
evolution change is due to the selecting pressure for
Figure 4. The distribution of erythromycin resistance genes among erythromycin-resistant strains of group A streptococci iso-
lated from children during 2000e2012. a Resistance genes were not found in two erythromycin resistant isolates. Two resistance
genes were detected in a single isolate.
Macrolide resistance of GAS in children 165resistance or environment influences requires additional
study.
Epidemiological investigations suggested the spread of
some emm strains was responsible for the increasing
erythromycin resistance among GAS in several geographic
areas. Martin et al3 identified the spread of erythromycin-
resistant emm6 strains in Pittsburgh. A few emm28 clones
were associated with increasing resistance in French since
2002.15 In the current study, various emm types were
evident among erythromycin-resistant strains. emm4 and
emm12, mainly originated from nasopharynx, were the
most prevalent genotypes. emm12 strains were mainly
detected in 2001e2002, 2005e2006, and 2011e2012, and
emm4 strains in 2004 and 2008. Most emm12 isolates were
obtained from patients with upper respiratory tract infec-
tion. Higher macrolide resistance rates of emm12 isolatesFigure 5. Pulsed-field gel electrophoresis patterns of SmaI res
strains. A dendrogram was generated with Bionumerics software (Amay be related to overuse of macrolide in these patients. A
PFGE study of nine erythromycin-resistant emm12 isolates
randomly collected in 2011 and in 2012 showed almost the
same PFGE among the isolates. The single clone of eryth-
romycin resistant emm12 strain may be predominant in the
community. However, there was no obvious outbreak of
GAS infection during the recent 2 years.
In conclusion, not only a steady decline of erythromycin
susceptibility but also the decreasing azithromycin and
clindamycin susceptibility of the GAS strains was observed
in southern Taiwan. This trend might be due to a complex
interplay of different contributions, including possible
increasing antibiotics consumption in the community, or
the clonal spread of erythromycin-resistant strains. mefA
and ermB contained strains remained the major mechanism
of erythromycin resistance in this area. ermB and ermTRtricted chromosomal DNA of Streptococcus pyogenes emm12
pplied Maths, Sint-Martens-Latem, Belgium).
166 P.-K. Chuang et al.contained strains were more frequent to have cross-
resistance to more than two classes of antimicrobial
agents. Whether the changes of antibiotics resistance and
the molecular characterization among GAS isolates repre-
sents a trend or is just a temporal variation needs further
surveillance.
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